{"filings":[{"id":1314678,"accession_number":"0001193125-26-286747","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2026-06-29T10:05:21+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Inhibikase stockholders approve 3M share increase under equity plan and director elections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2020 Equity Incentive Plan increasing authorized shares by 3,000,000.","Certificate of incorporation amended to limit liability of certain officers as permitted by Delaware law.","Arvind Kush (70.3M for) and Dennis Berman (64.1M for) elected as Class III directors to 2029 meeting.","CohnReznick LLP ratified as independent auditor for fiscal 2026 with 106.9M votes for.","Advisory vote on executive compensation passed; company will hold future say-on-pay votes annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":41242,"accession_number":"0001193125-26-219610","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2026-05-12T20:31:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibikase Q1 2026 net loss $16.4M; first patient enrolled in Phase 3 PAH study IMPROVE-PAH","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.4M ($0.10 EPS) vs $13.7M ($0.15) in Q1 2025; cash & equivalents $170.4M as of Mar 31, 2026.","First patient enrolled in registrational Phase 3 IMPROVE-PAH study for IKT-001 in PAH; EMA approved 12 EU countries, total 16 countries.","R&D expenses $10.8M (incl. one-time non-cash $7.4M from CorHepta acquisition in prior year); SG&A $7.4M.","Upcoming presentations at ATS May 17 and 20, 2026 on safety/tolerability/PK and preclinical efficacy of IKT-001."],"consensus_eps_estimate":-0.1094,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95172,"accession_number":"0001193125-26-144582","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibikase enrolls first patient in Phase 3 PAH study of IKT-001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled in global pivotal Phase 3 IMPROVE-PAH trial (NCT07365332).","Part A: ~140 patients, primary endpoint change in PVR at Week 24, double-blind placebo-controlled.","Part B: ~346 patients, primary endpoint change in 6MWD at Week 24, seamless transition from Part A.","Adaptive design includes a 12-week dose-titration phase; FDA confirmed study plan.","Trial to be conducted at up to ~180 sites worldwide; NDA filing timeline accelerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108049,"accession_number":"0001193125-26-126322","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibikase reports FY2025 net loss $48.3M; advances IKT-001 into Phase 3 PAH trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $48.3M ($0.49/share) for FY2025 vs $27.5M ($1.16/share) in FY2024.","Cash and marketable securities $178.8M at Dec 31, 2025, up from $97.5M.","Closed $115M public offering of common stock and pre-funded warrants in Nov 2025.","Initiated global adaptive Phase 3 IMPROVE-PAH study for IKT-001 in PAH; Part A (140 pts, PVR) then Part B (346 pts, 6MWD).","Regulatory submissions in >20 countries; FAST-EU acceptance for accelerated trial approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124473,"accession_number":"0001193125-25-326916","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inhibikase Therapeutics files prospectus supplement for $185M ATM offering via Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Inhibikase may sell up to $185M of common stock under existing ATM program through Jefferies LLC.","Prospectus supplement filed Dec 19, 2025, under registration statement on Form S-3 (File 333-288213).","Sales Agreement with Jefferies LLC was originally dated June 20, 2025.","No specific use of proceeds stated; offering conducted from time to time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124472,"accession_number":"0001193125-25-291443","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Inhibikase raises ~$93.6M in public offering, advances IKT-001 to Phase 3 PAH trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 46.1M shares at $1.45/share and pre-funded warrants for 22.9M shares; net proceeds ~$93.6M.","Underwriters granted 30-day option to purchase up to 10.3M additional shares.","Company amended Series A-1 and B-1 warrants to reflect plan to advance IKT-001 to global pivotal Phase 3 trial in PAH.","Offering expected to close November 24, 2025; shelf registration effective June 27, 2025.","Jefferies, BofA Securities, and Cantor Fitzgerald are representatives of the underwriters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124471,"accession_number":"0001193125-25-289768","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IKT advances IKT-001 to global pivotal Phase 3 in PAH; ATM prospectus terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IMPROVE-PAH Phase 3 trial for IKT-001 in pulmonary arterial hypertension expected to start Q1 2026 across up to 180 sites.","Adaptive two-part design: Part A (140 pts, primary endpoint PVR at Week 24) and Part B (346 pts, primary endpoint 6MWD at Week 24).","Prior Phase 2b plan replaced after FDA Type C meeting; company cites advantages of uninterrupted enrollment and dose titration.","ATM prospectus terminated with no sales made; Sales Agreement with Jefferies remains in effect without further sales pending new filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124470,"accession_number":"0001193125-25-283075","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibikase Q3 net loss $11.9M ($0.13/sh); advancing IKT-001 Ph2b in PAH","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.9M for Q3 2025 vs $5.8M YoY; cash $77.3M at Sep 30, down from $97.5M at Dec 2024.","R&D expenses $7.6M (Q3) vs $4.2M; includes $7.4M IPR&D write-off from CorHepta acquisition.","Plans to initiate Phase 2b IMPROVE-PAH trial of IKT-001 in Q4 2025 (150 pts; 300/500 mg or placebo).","Appointed Timothy Pigot as Chief Commercial and Strategy Officer.","To present at Jefferies Global Healthcare Conference on Nov 17, 2025."],"consensus_eps_estimate":-0.1313,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141133,"accession_number":"0001193125-25-180889","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Inhibikase Q2 net loss $9.9M; Phase 2b IKT-001 PAH trial to start H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $87.7M at June 30, 2025, vs $97.5M at Dec 31, 2024.","Net loss $9.9M ($0.11/share) for Q2 2025 vs $5.0M ($0.66/share) in Q2 2024.","R&D expenses $5.3M in Q2 2025, up from $3.1M in Q2 2024; SG&A $5.9M vs $2.0M.","Phase 2b IMPROVE-PAH study of IKT-001 (prodrug of imatinib) to begin H2 2025.","Primary endpoint: change in pulmonary vascular resistance at Week 26; secondary include 6MWD."],"consensus_eps_estimate":-0.0909,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158938,"accession_number":"0001193125-25-152767","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inhibikase stockholders re-elect directors, ratify auditor, approve equity plan amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amit Munshi and David Canner re-elected as Class II directors with 56.8M and 57.7M votes for, respectively; 3.4M broker non-votes.","CohnReznick LLP ratified as independent auditor for FY2025: 61.1M votes for, 29k against, no broker non-votes.","Amendment to 2020 Equity Incentive Plan (evergreen provision) approved: 46.3M for, 11.4M against, 3.4M broker non-votes.","Annual meeting held June 27, 2025; no other matters voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158937,"accession_number":"0001193125-25-119939","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibikase Q1 net loss $13.7M; advancing IKT-001 PAH Ph2b trial in H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.7M ($0.15/share) vs $4.6M ($0.73) in Q1 2024; includes $7.4M non-cash acquisition charge for CorHepta.","R&D expenses $10.5M (incl. $7.4M IPR&D charge); SG&A $5.2M; cash $93.2M at March 31, 2025.","Appointed new CEO (Mark Iwicki), President/Head of R&D (Chris Cabell), CSO (John Adams), CFO (David McIntyre).","IKT-001 Phase 2b PAH study design finalizing; trial initiation expected H2 2025; FDA 'Study May Proceed' received Sept 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158936,"accession_number":"0001193125-25-079656","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inhibikase Therapeutics appoints David McIntyre as CFO as Garth Lees-Rolfe resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Garth Lees-Rolfe resigned as CFO effective April 11, 2025; not due to any dispute with the Company.","David McIntyre appointed CFO effective April 14, 2025; previously CFO of Anthos Therapeutics and partner at Apple Tree Partners.","McIntyre receives $485,000 base salary, 45% target bonus, and 3,142,967 stock options.","Lees-Rolfe to consult through Aug 15, 2025 at $33,333/month; options continue vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177359,"accession_number":"0001193125-25-065511","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibikase reports 2024 net loss $27.5M; cash $97.5M; PAH trial progress, new leadership","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.5M ($1.16 per share) vs $19.1M ($3.16 per share) in 2023; R&D $17.2M, SG&A $11.4M.","Cash, cash equivalents and marketable securities $97.5M as of December 31, 2024.","Closed $110M private placement in October 2024 (up to $275M if warrants exercised).","Appointed Mark Iwicki CEO, Chris Cabell President & Head of R&D, John Adams CSO; added new board members.","Received Study May Proceed letter for Phase 2b trial of IkT-001 in PAH in September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177358,"accession_number":"0001193125-25-032821","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Inhibikase acquires CorHepta for $15M in stock; appoints Cabell as President and Adams as CSO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired CorHepta for $15M in stock: 4,979,101 shares issued (3,319,397 upfront, remainder contingent on milestone).","Chris Cabell appointed President & Head of R&D; former CorHepta CEO and ex-CMO of Arena Pharmaceuticals.","Vincent Aurentz appointed to Board; former EVP/Chief Business Officer at Arena (acquired by Pfizer for $6.7B).","John Adams appointed Chief Scientific Officer; co-founder of CorHepta, former Head of Research at Arena.","Dr. Cabell employment: $500K base, 45% bonus, 2.81M stock options vesting over 4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177357,"accession_number":"0001193125-25-028188","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inhibikase appoints Mark Iwicki as CEO; founder Milton Werner resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Milton Werner resigned as CEO/board member effective Feb 13, 2025; will consult through May 13, 2025 at $44,583/month.","Mark Iwicki appointed CEO, President and director effective Feb 14, 2025; base salary $710K, bonus up to 60%, options for 15.1M shares.","Amit Munshi named independent Chair of the Board, replacing Roberto Bellini who remains a director.","Company advancing IkT-001Pro in Phase 2b trial with $110M from October financing; new CEO has PAH expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177356,"accession_number":"0001193125-25-015648","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Inhibikase Phase 2 risvodetinib trial misses primary efficacy endpoint; development paused","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial enrolled 126 untreated Parkinson's patients; 95% completed 12 weeks with safety comparable to placebo.","No improvement on primary efficacy measure MDS-UPDRS Parts 2+3 at any dose vs placebo.","Secondary signals: Part 2 improved -1.41 at 100 mg (p=0.036); Schwab & England +4% at 50 mg (p=0.0004).","Skin biopsy analysis suggests treatment-dependent reduction in neuronal alpha-synuclein deposition.","Company pausing risvodetinib to focus resources on IkT-001Pro for PAH; evaluating strategic options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177355,"accession_number":"0001193125-25-001787","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Inhibikase shareholders approve 5x authorized share increase to 500M and option repricing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase in authorized common shares from 100M to 500M; Certificate of Amendment filed Jan 3, 2025.","Approved elimination of 66 2/3% supermajority vote requirement for amendments to Article IV.","Approved 27,453,993 share increase in 2020 Equity Incentive Plan reserve.","Approved repricing of certain outstanding stock options; all proposals passed with >97% of votes cast.","Vote results: share increase – 62.5M for, 377K against; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194108,"accession_number":"0001193125-24-271609","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Inhibikase terminates unused ATM facility; no impact on capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated ATM agreement with H.C. Wainwright effective Dec 11, 2024.","Original ATM limit was $5.66M; only $849k sold before reduction to $50k.","No shares sold under ATM since May 20, 2024.","Termination ends ability to issue equity at market via this facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194107,"accession_number":"0001193125-24-240603","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Inhibikase closes $110M private placement, up to $275M total, advances IkT-001Pro in PAH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$110M from private placement; potential aggregate up to ~$275M from warrant exercises.","Proceeds to fund Phase 2b '702' trial of IkT-001Pro in PAH and for general corporate purposes.","Appointed four new directors: Roberto Bellini (Independent Chair), Amit Munshi, David Canner, Arvind Kush.","Resignations of Dr. Paul Grint and Gisele Dion, not due to disagreements; fully vested options paid through Dec 31, 2024.","IkT-001Pro is oral, potentially disease-modifying imatinib prodrug aiming to improve safety/tolerability in PAH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194106,"accession_number":"0001193125-24-236039","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["1.01","5.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Inhibikase raises ~$110M in private placement; appoints four new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$110M from common stock, pre-funded warrants, and Series A-1/B-1 warrants at $1.37 per share unit.","Company to seek stockholder approval to increase authorized shares; meeting within 90 days of close of offering.","Board expands from 5 to 7; appoints Bellini, Munshi, Kush, Canner effective Oct 21.","Series A-1 warrants ($1.37) expire 30 days after Phase 2b safety readout; Series B-1 ($1.49) after efficacy readout.","New directors invest alongside: BSquared $2M, Munshi family $500K, Kush trust $200K, Soleus Capital ~$21.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194105,"accession_number":"0001193125-24-234814","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibikase posts new corporate presentation highlighting PAH clinical program","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["New company presentation made available on investor relations website October 9, 2024.","Presentation focuses on clinical development of disease-modifying therapeutics for pulmonary arterial hypertension (PAH).","No specific financial results, trial data, or guidance disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210420,"accession_number":"0001193125-24-194177","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inhibikase shareholders approve warrant issuance for private placement","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Special Meeting held Aug 5, 2024; single proposal approved with 3,579,141 votes for.","Proposal: approve issuance of common stock purchase warrants under Nasdaq Listing Rule 5635(d).","Against: 84,029 votes; abstentions: 85,025; no broker non-votes.","Warrants relate to a private placement and a warrant inducement; no terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228751,"accession_number":"0001193125-24-158318","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inhibikase shareholders approve equity plan increase; charter amendment fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Milton H. Werner re-elected with 2,993,996 votes for, 100,914 withheld.","Ratification of CohnReznick as auditor passed with 4,352,312 for, 21,268 against.","Amendment to 2020 Equity Incentive Plan (increase of 2.5M shares) approved with 2,706,691 for.","Proposal to eliminate 66 2/3% vote requirement for charter amendments failed (2,929,207 for, 120,362 against).","All results include substantial broker non-votes on director election and equity plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228750,"accession_number":"0001193125-24-142317","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Inhibikase raises $4.0M in registered direct offering and warrant inducement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,672,452 shares (or pre-funded warrants) at $1.68/unit with Series A and B warrants.","Warrant inducement: immediate exercise of 708,500 existing warrants at $1.68; repricing of 1,229,484 warrants.","Series A/C warrants exercisable 12 months; Series B/D warrants exercisable 5 years from stockholder approval.","Gross proceeds ~$4.0M; expected closing May 22, 2024; Maxim Group sole placement agent.","Proceeds for general corporate purposes; stockholder approval required for warrant exercisability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228749,"accession_number":"0001193125-24-123758","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Inhibikase receives arbitration demand for $1.625M from Pivot over milestone payments","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Pivot Holding LLC, successor to Sphaera Pharma, demands $1.625 million plus interest for alleged breach of 2012 collaboration agreement.","Company believes claims are without merit and will vigorously dispute; intends to assert counterclaims.","Arbitration proceeding administrated by American Arbitration Association; no timeline for resolution disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228748,"accession_number":"0001193125-24-101292","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibikase 201 trial ~75% enrolled; expects completion by mid-June 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["201 Trial (risvodetinib) ~75% enrolled, 30 patients left; enrollment completion expected mid-June 2024.","Plan to initiate a 12-month extension study; requires additional capital.","Pre-IND meeting with FDA for IkT-001Pro in PAH completed; pre-NDA for cancer indications held.","Submitted grants to NINDS/NIH for biomarker development including new monoclonal antibody.","Expects end-of-Phase 2 meeting with FDA by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228747,"accession_number":"0001193125-24-084902","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K/A","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inhibikase Therapeutics discloses CFO Lees-Rolfe's compensation: $345K salary, 90K option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $345,000 per annum with discretionary annual target bonus of 30% of base.","Initial stock option for 90,000 shares at $2.16, vesting in three equal annual installments.","Non-CIC termination severance: 9 months base salary plus COBRA reimbursement for 9 months.","CIC termination (within 12 months post-change): 12 months base salary lump sum, full equity vesting, one-time Target Bonus.","Employment Agreement effective April 1, 2024; role as Chief Financial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247390,"accession_number":"0001193125-24-025941","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inhibikase receives FDA guidance on 505(b)(2) path for IkT-001Pro; Parkinson's trial enrolling 51 patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA pre-NDA meeting on Jan 19, 2024: acknowledges 505(b)(2) pathway appropriate for IkT-001Pro in blood/gastrointestinal cancers.","Bioequivalence shows 600mg/800mg IkT-001Pro similar to 400mg/600mg imatinib; FDA advises evaluating doses up to 800mg.","Company to seek all 11 imatinib indications; must conduct gut transporter studies and use-related risk analysis.","Risvodetinib 201 Trial: 32 sites open, 51 enrolled, 23 completed 12 weeks, 10 mild/moderate AEs reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247389,"accession_number":"0001193125-24-021850","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Inhibikase signs $5.66M ATM equity distribution agreement with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into ATM equity offering agreement with H.C. Wainwright for up to $5,659,255 of common stock.","Agent receives 3.0% commission on gross proceeds; company reimburses up to $50k initial legal fees plus $2.5k quarterly.","Sales made under existing effective S-3 shelf registration statement (File No. 333-262551) at market prices.","Company has no obligation to sell shares and may suspend or terminate the agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247388,"accession_number":"0001193125-24-008593","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Inhibikase CFO Joseph Frattaroli to retire; Garth Lees-Rolfe promoted as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Frattaroli to retire as CFO effective March 31, 2024; vested stock option exercise period extended.","Garth Lees-Rolfe, current VP of Finance since Nov 2022, will become CFO upon Frattaroli's retirement.","Lees-Rolfe previously VP Finance at F-Star and spent 16 years in public practice, including at Ernst & Young.","Retirement is not due to any disagreement with the Company; transition is planned and orderly.","Compensation for Lees-Rolfe as CFO not yet determined; to be disclosed in a future 8-K amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282034,"accession_number":"0001193125-23-238295","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibikase provides pipeline updates after sharp stock decline; 201 Trial enrollment at 28 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock dropped dramatically over last 8 trading sessions; no identifiable cause for volatility.","Risvodetinib 201 Trial: 28 of 120 patients enrolled/screening; one completed 12-week dosing; portal added 50 potential participants in Sept.","Safety data for risvodetinib presented on 119 people at MDS Congress; no side effects of clinical significance.","IkT-001Pro: FDA meeting request steps completed; bioequivalence study to 600 mg imatinib mesylate due early Q4 2023.","Cash position sufficient to fund operations into Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282033,"accession_number":"0001193125-23-188223","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Inhibikase regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 17, 2023 confirming compliance with Listing Rule 5550(a)(2).","Closing bid price was at or above $1.00 for 10 consecutive business days ended July 14, 2023.","The matter is closed; no further action required from the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301119,"accession_number":"0001193125-23-178328","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Inhibikase Therapeutics announces 1-for-6 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective June 30, 2023; shares outstanding reduced from ~31.6M to ~5.3M.","Stockholder approval obtained on June 23, 2023; no fractional shares issued, fractional holders get full share.","CUSIP changed to 45719W205; trading symbol remains 'IKT'.","Proportional adjustments made to stock options and warrants exercise prices and shares.","Split intended to meet Nasdaq minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301118,"accession_number":"0001193125-23-176725","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inhibikase Therapeutics shareholders reject share increase, approve reverse split at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dennis Berman and Gisele Dion elected as Class III directors with 16.3M and 16.7M votes for, respectively.","Proposal to increase authorized shares from 100M to 200M failed (20.6M for, 2.2M against; not enough votes).","Approved reverse stock split authorization (1-for-5 to 1-for-20) with 21.9M votes.","Proposal to eliminate supermajority vote requirement for charter amendments failed (15.5M for, 6.1M broker non-votes).","Ratification of CohnReznick as auditor passed with 22.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321001,"accession_number":"0001193125-23-076674","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibikase Therapeutics holds R&D Day; presentation content not fully available in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented to investors at R&D Day on March 22, 2023.","The 8-K includes presentation as Exhibit 99.1 but only title slide and disclaimer are visible in the filing excerpt.","No specific pipeline data, financial figures, or clinical milestones are extractable from the provided text.","Investors should consult the full presentation on the company's website or other SEC filings for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321000,"accession_number":"0001193125-23-069219","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Inhibikase Therapeutics discloses no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds no cash deposits or lines of credit with SVB.","No business relationship with SVB exists.","Filing aims to reassure investors amid SVB collapse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320999,"accession_number":"0001193125-23-061524","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Inhibikase Therapeutics awards stock options to CEO and CFO with performance vesting tied to Phase 2a study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Milton H. Werner granted options for 315,000 shares at $0.7390; 105,000 subject to performance vesting.","CFO Joseph Frattaroli granted options for 135,000 shares at $0.7390; 45,000 subject to performance vesting.","Performance milestones tied to completion and release of IKT-148009 Phase 2a study in Parkinson's disease.","Remaining options subject to time vesting under 2020 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320998,"accession_number":"0001193125-23-016224","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["1.01","1.02","3.02","7.01","9.01"],"status":"ready","headline":"Inhibikase raises ~$10M via registered direct offering and private placement with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 6,744,187 shares/equivalents at $0.86/share in registered direct, plus 4,883,721 in private placement.","Issued unregistered warrants to purchase up to 11,627,908 shares at $0.75/share, exercisable for 5 years.","Gross proceeds ~$10M; net proceeds for clinical trials, product development, and working capital.","Terminated prior at-the-market equity distribution agreement with Piper Sandler (no sales made).","H.C. Wainwright acted as exclusive placement agent; offering expected to close January 27, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320997,"accession_number":"0001193125-23-014850","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts full clinical hold on Inhibikase's IkT-148009 for Parkinson's; Phase 2a trial restarting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted full clinical hold on IkT-148009; Phase 2a 201 trial resumes at 50 and 100 mg doses.","Company will measure safety and steady-state PK of 200 mg in 6 healthy subjects before PD patient dosing.","Expanded ocular monitoring includes cornea/lens; no ocular pathology observed to date.","Inhibikase intends to seek lift of clinical hold on its Multiple System Atrophy (MSA) program.","Publication in Science Translational Medicine shows IkT-148009 halts neurodegeneration and reduces alpha-synuclein pathology in mouse models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320996,"accession_number":"0001193125-23-014226","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Inhibikase receives Nasdaq extension to July 24, 2023 to regain $1 minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted additional 180-day period until July 24, 2023 to meet Minimum Bid Price Requirement.","Compliance requires closing bid price at least $1.00 for 10 consecutive business days.","Company previously disclosed deficiency on July 25, 2022; intends to cure via reverse stock split if needed.","Failure to demonstrate compliance by July 24, 2023 will result in Nasdaq delisting notice, with appeal rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339110,"accession_number":"0001193125-22-287698","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-11-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Inhibikase Q3 net loss $4.49M; FDA clinical hold on IkT-148009 programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 net loss of $4.49M ($0.18 per share) vs. $4.47M in Q3 2021.","Cash, cash equivalents and marketable securities of $26.5M as of Sep 30, 2022.","R&D expenses were $2.98M for Q3 2022, down from $3.15M in Q3 2021.","FDA placed clinical hold on IkT-148009 for Parkinson's and MSA; 11 patients dosed with no serious adverse events.","Appointed Gisele Dion to Board of Directors as Audit Committee chair."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":59874.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339109,"accession_number":"0001193125-22-279041","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA imposes clinical hold on Inhibikase's IkT-148009 Parkinson's and MSA programs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed a clinical hold on the IkT-148009 201 program in Parkinson's disease and its use in Multiple Systems Atrophy (MSA).","Inhibikase states no serious adverse events have been observed in the ongoing 201 trial to date.","Official clinical hold letter expected within 30 days; company is actively working with FDA to resolve concerns.","IkT-148009 is a protein kinase inhibitor for neurodegenerative diseases; no timeline for hold resolution given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356478,"accession_number":"0001193125-22-246370","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-09-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibikase Therapeutics presents Phase 1/1b data for IkT-148009 in Parkinson's; Phase 2 ongoing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/1b of IkT-148009 (88 healthy, 13 PD patients) showed no clinically significant AEs, linear PK, and CNS penetration over 12.5-325 mg daily doses.","In PD mouse models, once-daily oral IkT-148009 preserved >80% SNpc neurons, improved motor function, and reduced pathological alpha-synuclein aggregates.","C-Abl activation is required for PD initiation; IkT-148009 is a selective brain-penetrant c-Abl inhibitor with no organ toxicity seen in toxicology studies.","Phase 2 3-month dosing study (NCT05424276) in mild-to-moderate PD patients has begun to evaluate efficacy and disease modification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356477,"accession_number":"0001193125-22-236658","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Inhibikase appoints Gisele Dion to Board, replacing retiring Elizabeth O'Farrell","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth O'Farrell retired from the Board effective Sep 1, 2022; departure not due to any disagreement.","Gisele Dion appointed as Class III director effective Sep 1, 2022.","Dion receives $65k annual cash and a 60,000-share option grant (50% vest each of first two anniversaries).","Dion previously SVP & CAO at Takeda, CAO at Shire, and board member at Cytek Biosciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356476,"accession_number":"0001193125-22-221288","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibikase posts corporate presentation; no specific financial or clinical data in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation made available on company website on Aug 15, 2022, for investor presentations.","Filing includes only cover page and disclaimer; full slide deck not reproduced in the 8-K.","Presentation is dated 3Q 2022 and focuses on neurodegenerative disease and cancer therapeutics.","No new financial results, guidance, or clinical milestones were disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356475,"accession_number":"0000950170-22-013406","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Inhibikase receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice dated July 25, 2022; stock bid price below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until January 23, 2023, to regain compliance.","To cure, closing bid price must be at least $1.00 for 10 consecutive business days.","Failure may lead to a second 180-day cure period or delisting, subject to appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374909,"accession_number":"0000950170-22-012322","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Inhibikase Therapeutics 2022 Annual Meeting results: share count increase fails","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Roy Freeman and Paul Grint elected with ~11.4M and ~11.5M votes for; ~4.5M broker non-votes.","Ratification of CohnReznick LLP as auditor approved: 16.4M for, 31.5K against, 56.6K abstain.","Proposal to increase authorized shares from 100M to 200M failed: 15M for, 1.4M against, not meeting required percentage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374908,"accession_number":"0001193125-22-152247","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Inhibikase Therapeutics enters ATM equity distribution agreement for up to $9.8M through Piper Sandler","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate offering price up to $9,801,287 of common stock; sales at market prices via Piper Sandler.","Agent receives 3.0% commission on gross proceeds; expense reimbursement up to $75k upfront + $15k per quarter.","Sales made under existing shelf registration (Form S-3, File 333-262551) effective Feb 2022.","Company has no obligation to sell; may suspend or terminate the agreement at any time.","Customary representations, warranties, and indemnification provisions included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374907,"accession_number":"0001193125-22-113033","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibikase posts corporate presentation; no material updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made corporate presentation available on April 21, 2022 via its website.","Presentation covers clinical development of disease-modifying therapeutics for Parkinson's and related disorders.","Filing contains no new financial or operational data; presentation content not fully available in the 8-K.","No specific pipeline milestones, revenue, or guidance changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393327,"accession_number":"0001193125-22-083462","cik":1750149,"company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Inhibikase presents Phase 1/1b data at AD/PD 2022; no numerical results in 8-K","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented Phase 1 and 1b clinical study results at AD/PD Conference in Barcelona on March 18, 2022.","Presentation focuses on Abl-kinase inhibition (IKT-148009) for Parkinson's disease modification.","No specific quantitative outcomes, milestones, or financial impact disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":227756308.05882353,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-24T23:59:59+00:00|393327"}